University of Patras
Μελέτη μηχανισμών επαγωγής αυτοανοσίας σε ασθενείς με συστηματικά ρευματικά νοσήματα που λαμβάνουν θεραπεία με αντι-TNFα βιολογικούς παράγοντες
Abstract
dc:descriptionBiologic agents against ΤΝFα have been widely used for the management of systemic inflammatory disorders, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn’s disease. However, it soon became apparent that patients under ΤΝFα blockade commonly develop serologic autoimmune manifestations. Emergence of ANA, usually of the IgM isotype, is common in anti-TNFα treated patients and a few of these patients may develop a SLE-like syndrome. B cells are implicated in the pathogenesis of SLE and are characterized by enhanced tyrosine phosphorylation of proteins following BCR ligation and reduced expression of Lyn, a Src-family kinase abundantly expressed in B cells with both stimulatory and inhibitory properties on the BCR-signaling pathway. Reduced levels of B-cell surface CD21 (complement receptor type 2) and increased expression of CD20 have also been described for lupus B cells. To dissect the mechanisms of anti-ΤΝFα induced autoimmunity we examined the phenotype and function of B cells prior to and following treatment with ΤΝFα antagonists. Levels of Lyn, Syk, SHP-1, tyrosine 348 phospho-Syk (PY348-Syk) and tyrosine phosphorylated proteins were evaluated in 29 patients before and following treatment with TNFα blockers using western immunoblots. B-cell surface expression of CD20, CD21 and CD5 were also assessed with flow cytometry. Following treatment, B cell cytoplasmic levels of Lyn, but not Syk or SHP-1, significantly increased following treatment with anti-ΤΝFα agents, particularly in patients with spondyloarthropathies. Increased Lyn levels following treatment correlated with increased Lyn enzymatic activity as evidenced by a 2.9-fold increase of PY348-Syk levels, which comprises a Lyn-specific target. Moreover, unstimulated peripheral B cells from anti-ΤΝFα treated patients displayed a tendency towards increased tyrosine phosphorylated proteins following treatment. CD20, a B-cell restricted signaling-associated molecule implicated in the regulation of intracellular calcium levels following BCR ligation, significantly increased in patients with rheumatoid arthritis following treatment with anti-ΤΝFα agents whereas levels of CD21 remained unchanged. Circulating CD5+ B cells, a B-cell subpopulation and a known source of natural autoantibodies, were also significantly expanded during treatment. Our findings suggest that B cells in anti-ΤΝFα treated patients display functional and phenotypical aberrations that may be associated with the induction of autoimmunity, but do not acquire a typical idiopathic SLE profile. These aberrations are distinct from those previously described for lupus B cells and may thus represent a different model of autoimmunity. Further studies regarding the mechanisms underlying the induction of autoimmunity by TNFα antagonists may enhance our understanding on the molecular backgrounds and the pathogenesis of other autoimmune inflammatory disorders.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karampetsou, Maria
- Καραμπέτσου, Μαρία
Subjects
dc:subject × 19- Αυτοανοσία
- Αντι-TNFα βιολογικοί παράγοντες
- Β λεμφοκύτταρα
- Κινάση Lyn
- Αγκυλοποιητική σπονδυλίτιδα
- Ρευματοειδής αρθρίτιδα
- Autoimmunity
- Anti-TNFa biologic agents
- B-cells
- Kinase Lyn
- CD20
- Ankylosing spondylitis
- Rheumatoid arthritis
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35534